Regulatory legitimacy: the case for controlling and restricting access to PGD for sex-selection purposes
Chalmers, DRC, Regulatory legitimacy: the case for controlling and restricting access to PGD for sex-selection purposes, Regulating Pre-Implantation Genetic Diagnosis: A comparative and theoretical analysis, Routledge, Sheila A.M. McLean and Sarah Elliston (ed), Oxford, pp. 148-170. ISBN 9780415686440 (2013) [Research Book Chapter]
Pre-implantation genetic diagnosis embryo screening and assisted reproductive technology
Thirty years after the first birth using in vitro fertilisation (IVF), the assisted reproductive technology (ART) debates have continued, raising issues concerning embryo experimentation, including the use of pre-implantation genetic diagnosis (PGD) to screen embryos for genetic characteristics and conditions. PGD is used to screen embryos to assist in deciding which may be judged suitable for implantation. Those not deemed suitable are generally discarded, although they may be used for research purposes, given that any required consent has been obtained. This chapter examines the regulatory regime for PGD in Australia which can be found principally in the National Health and Medical Research Council's (NHMRC) Ethical Guidelines on the Use of Assisted Reproductive Technology and Clinical Practice and Research (2007). Where PGD is used in embryo research, the regulatory regime established by the Research Involving Human Embryos Act 2002 applies. An Australian government committee reviewed this regime, which resulted in revisions to the NHMRC guidelines and to the legislation. This chapter focuses on PGD embryo screening and the regulatory justifications for controlling and restricting access to PGD in ART clinical procedures, with specific reference to its use in sex selection for non-medical reasons.